Xcout Intel
Cerevance
Cerevance is a pharmaceutical and biotechnology research company based in Boston, Massachusetts, that uses its proprietary NETSseq platform to develop cell-type specific treatments. The company focuses on neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders.
Subscribe to see Cerevance’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Cerevance at a glance
Cerevance is a biotechnology company headquartered in United States. Its most recent funding round, Series B-1 Extension, raised $47M in April 2024. Xcout tracks 3 named people at Cerevance, including Craig Thompson (Chief Executive Officer).
Cerevance leadership
- Craig ThompsonChief Executive Officer
- Sagar VaidyaChief Medical Officer
- Sarah Isabel SheikhMember of the Board of Directors
Cerevance funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B-1 Extension | $47M | 8 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Cerevance competitors
A few of Cerevance's closest competitors — see the full list of competitors and alternatives →
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Cajal Neuroscience (Cajal Therapeutics Inc.) is a biotechnology company headquartered in Seattle, Washington. The company is dedicated to advancing therapeutic pipelines in neuroscience research.
Congruence Therapeutics is a clinical-stage biotechnology company located in Montreal, Quebec, that discovers and develops small molecule correctors and allosteric modulators for protein-misfolding diseases.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Herophilus is a neurotherapeutics discovery company headquartered in San Francisco, California. The company utilizes artificial intelligence, human stem cell models, and phenotypic screening platforms to discover and develop new drugs for neurodegenerative and neurological diseases.
Dewpoint Therapeutics is an integrated drug discovery platform company headquartered in Boston, Massachusetts. The firm leverages advanced biotechnology to translate condensate biology into novel medicines for various therapeutic areas.
Get Cerevance's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Cerevance in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access